Canaccord Genuity on Life Sciences: A Clinical Lab Perspective of C. Difficile Testing
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity on Life Sciences -- Biomedical Devices and Services - A clinical lab perspective of C. difficile testing
Canaccord analyst, Jeffrey Frelick, said, "The American Association of Clinical Chemistry recently hosted an expert access presentation that featured Dr. Eileen Burd, Director of Clinical Microbiology and Laboratory Medicine at Emory University Hospital. Dr. Burd discussed the use of molecular tests for the diagnosis and management of C. difficile. We reiterate our BUY ratings on Cepheid (Nasdaq: CPHD) and Meridian Bioscience (Nasdaq: VIVO) given the endorsement from Dr. Burd’s comments that the world is moving toward molecular testing based upon the superior sensitivity and improvements in ease of use. In addition, Cepheid and Meridian Bioscience are currently garnering most of the C. difficile molecular testing."
Canaccord analyst, Jeffrey Frelick, said, "The American Association of Clinical Chemistry recently hosted an expert access presentation that featured Dr. Eileen Burd, Director of Clinical Microbiology and Laboratory Medicine at Emory University Hospital. Dr. Burd discussed the use of molecular tests for the diagnosis and management of C. difficile. We reiterate our BUY ratings on Cepheid (Nasdaq: CPHD) and Meridian Bioscience (Nasdaq: VIVO) given the endorsement from Dr. Burd’s comments that the world is moving toward molecular testing based upon the superior sensitivity and improvements in ease of use. In addition, Cepheid and Meridian Bioscience are currently garnering most of the C. difficile molecular testing."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
